Table 3.
Univariate Analysis of Predictors of Dropout Due to Tumor Progression or Death by Competing Risks
| Univariate SHR (95% CI) | p-value | |
|---|---|---|
| Patient Characteristics at Listing | ||
| Age (per year) | 0.98 (0.96–1.01) | 0.21 |
| Female Gender | 0.93 (0.57–1.52) | 0.78 |
| Etiology of liver disease (vs HCV) | ||
| HBV | 0.73 (0.44–1.21) | 0.22 |
| Others | 0.81 (0.44–1.5) | 0.5 |
| MELD (per point) | 1.04 (1.01–1.09) | 0.049 |
| Child’s C vs A | 1.65 (0.87–3.12) | 0.13 |
| Child’s B vs A | 1.20 (0.77–1.86) | 0.42 |
| Tumor Characteristics at Listing | ||
| 3 lesions vs 1 lesion 2–3cm | 7.76 (3.63–16.58) | <0.001 |
| 1 lesion 3.1–5cm vs 1 lesion 2–3cm | 4.31 (2.32–8.01) | <0.001 |
| 2 lesions vs 1 lesion 2–3cm | 2.85 (1.42–5.72) | 0.003 |
| AFP (ln) | 1.21 (1.11–1.32) | <0.001 |
| AFP>1000 vs ≤1000 | 2.59 (1.42–4.72) | 0.002 |
| AFP>500 vs ≤500 | 3.42 (2.03–5.74) | <0.001 |
| AFP>300 vs ≤300 | 2.35 (1.43–3.86) | 0.001 |
| AFP>100 vs ≤100 | 2.01 (1.31–3.09) | 0.001 |
| AFP>20 vs ≤20 | 1.91 (1.26–2.88) | 0.002 |
| Type of first LRT (versus TACE) | ||
| RFA | 1.10 (0.67–1.8) | 0.72 |
| Percutaneous ethanol injection | 1.30 (0.15–11.36) | 0.82 |
| Radiographic and AFP Response to first LRT | ||
| Partial Response vs Complete Response | 1.86 (0.98–3.54) | 0.06 |
| Stable Disease vs Complete Response | 5.75 (3.42–9.66) | <0.001 |
| Progressive Disease vs Complete Response | 25.62 (12.03–54.54) | <0.001 |
| AFP (ln) after 1st LRT | 1.29 (1.16–1.44) | <0.001 |
| AFP>1000 vs ≤1000 after 1st LRT | 4.05 (1.82–9.00) | 0.001 |
| AFP>500 vs ≤500 after 1st LRT | 4.93 (2.70–8.98) | <0.001 |
| AFP>300 vs ≤300 after 1st LRT | 3.28 (1.79–6.01) | <0.001 |
| AFP>100 vs ≤100 after 1st LRT | 2.78 (1.64–4.72) | <0.001 |
| AFP>20 vs ≤20 after 1st LRT | 2.16 (1.35–3.46) | 0.001 |